Effect of Toll-Like Receptor 3 Agonists on the Functionality and Metastatic Properties of Breast Cancer Cell Model

被引:0
|
作者
Alizadeh, Nastaran [1 ]
Amiri, Mohammad Mehdi [2 ]
Moghadam, Alireza Salek [1 ]
Zarnani, Amir Hassan [1 ]
Saadat, Farshid [3 ]
Safavifar, Farnaz [4 ]
Berahmeh, Azar [4 ]
Khorramizadeh, Mohammad Reza [4 ,5 ,6 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Pathobiol, Tehran, Iran
[3] Guilan Univ Med Sci, Sch Med, Dept Immunol, Rasht, Iran
[4] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Res Inst, Tehran, Iran
[5] Univ Tehran Med Sci, Biosensor Res Ctr, Endocrinol & Metab Mol Cellular Sci Inst, Tehran, Iran
[6] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran
关键词
MDA-MB-231; MMP-2; Poly (A:U); TLR3; APOPTOSIS; TLR3; PROLIFERATION; EXPRESSION; INDUCTION; RESPONSES; PROMOTES; ADJUVANT;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
There exists compelling evidence that Toll-like receptor 3 (TLR3) agonists can directly affect human cancer cells. The aim of this study was to investigate anti-cancer effects of TLR3 agonist in human breast cell line. We assessed potential effects of poly (A:U) on human breast cell line (MDA-MB-231) on a dose-response and time-course basis. Human breast cell line MDA-MB-231 was treated with different concentrations of poly (A:U) and lipopolysaccharide (LPS). Then, the following assays were performed on the treated cells:dose-response and time-course cytotoxicity using colorimetric method; matrix metalloproteinase-2 (MMP-2) activity using gelatin zymography method; apoptosis using annexin-v flowcytometry method; and relative expression of TLR3 and MMP-2 mRNA using reverse transcriptase polymerase chain reaction (RT-PCR) method. Following treatments, dose-response and time-course cytotoxicity using a colorimetric method, (MMP-2) activity (using gelatin zymography), apoptosis (using annexin-v flowcytometry method) assays and expression of TLR3 and MMP-2 genes (using PCR method) were performed. Cytotoxicity and flowcytometry analysis of poly (A:U) showed that poly (A:U) do not have any cytotoxic and apoptotic effects in different concentrations used. MMP-2 activity analysis showed significant decrease in higher concentrations (50 and 100 mu g/ml) between treated and untreated cells. Moreover, poly A:U treated cells demonstrated decreased expression of MMP-2 gene in higher concentrations. Collectively, our data indicated that human breast cancer cell line (MDA-MB-231) was highly responsive to poly (A:U). The antimetastatic effect of direct poly (A:U) and TLR3 interactions in MDA-MB-231 cells could provide new approaches in malignant tumor therapeutic strategy.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 50 条
  • [1] Toll-like receptor agonists and cancer
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (07) : 511 - 511
  • [2] Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
    Zhang, Christine
    Ben, Atheena
    Reville, Jade
    Calabrese, Victoria
    Villa, Nina Nicole
    Bandyopadhyay, Mausumi
    Dasgupta, Subhajit
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (09) : 1134 - 1140
  • [3] Toll-like receptor agonists targeted to cancer cell metabolism
    Mancini, Rock
    Nielsen, Amy
    Hantho, Joseph
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [4] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [5] Toll-Like Receptor 9 Agonists in Cancer
    Karapetyan, Lilit
    Luke, Jason J.
    Davar, Diwakar
    ONCOTARGETS AND THERAPY, 2020, 13 : 10039 - 10060
  • [6] Toll-Like Receptor 3 Signaling in Breast Cancer
    Yamashita, M.
    Bomeisl, P. E.
    Sen, G. C.
    Gilmore, H. L.
    LABORATORY INVESTIGATION, 2013, 93 : 76A - 76A
  • [7] Toll-Like Receptor 3 Signaling in Breast Cancer
    Yamashita, M.
    Bomeisl, P. E.
    Sen, G. C.
    Gilmore, H. L.
    MODERN PATHOLOGY, 2013, 26 : 76A - 76A
  • [8] Toll-Like Receptor 9 Agonists for Cancer Therapy
    Melisi, Davide
    Frizziero, Melissa
    Tamburrino, Anna
    Zanotto, Marco
    Carbone, Carmine
    Piro, Geny
    Tortora, Giampaolo
    BIOMEDICINES, 2014, 2 (03) : 211 - 228
  • [9] Toll-like receptor agonists in adjuvant immunotherapy for cancer
    Farkas, A.
    Urosevic, M.
    Dummer, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S21 - S21
  • [10] Toll-like receptor agonists as cancer vaccine adjuvants
    Jeon, Donghwan
    Hill, Ethan
    Mcneel, Douglas G.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)